1. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.
- Author
-
Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, Nikiforow S, Carter BS, Curry WT, Gallagher K, and Maus MV
- Subjects
- Humans, CD8-Positive T-Lymphocytes metabolism, Neoplasm Recurrence, Local therapy, ErbB Receptors antagonists & inhibitors, ErbB Receptors genetics, ErbB Receptors metabolism, Glioblastoma therapy, Glioblastoma pathology, Immunotherapy, Adoptive adverse effects, Receptors, Antigen, T-Cell genetics, Receptors, Antigen, T-Cell therapeutic use, Receptors, Chimeric Antigen therapeutic use
- Abstract
In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen, as well as the wild-type EGFR protein, through secretion of a T-cell-engaging antibody molecule (TEAM). Treatment with CARv3-TEAM-E T cells did not result in adverse events greater than grade 3 or dose-limiting toxic effects. Radiographic tumor regression was dramatic and rapid, occurring within days after receipt of a single intraventricular infusion, but the responses were transient in two of the three participants. (Funded by Gateway for Cancer Research and others; INCIPIENT ClinicalTrials.gov number, NCT05660369.)., (Copyright © 2024 Massachusetts Medical Society.)
- Published
- 2024
- Full Text
- View/download PDF